Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.

Amthor, Helge; Hoogaars, Willem M H

Amthor, Helge; Hoogaars, Willem M H.

Affiliation

Amthor H; Universite Pierre et Marie Curie, Institut de Myologie, Unite mixte de recherche UPMC-AIM UM 76, INSERM U 974, CNRS UMR 7215, 47-83, boulevard de l'Hopital, 75651 Paris Cedex 13, France. h.amthor@institut-myologie.org

Curr Gene Ther ; 12(3): 245-59, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22554312

Subject(s)

Activin Receptors, Type II; Molecular Targeted Therapy; Muscular Dystrophy, Duchenne; Myostatin/antagonists & inhibitors; Activin Receptors, Type II/antagonists & inhibitors; Activin Receptors, Type II/genetics; Activin Receptors, Type II/metabolism; Animals; Clinical Trials, Phase II as Topic; Humans; Mice; Mice, Inbred mdx; Muscle, Skeletal/growth & development; Muscle, Skeletal/metabolism; Muscle, Skeletal/physiopathology; Muscular Dystrophy, Duchenne/genetics; Muscular Dystrophy, Duchenne/metabolism; Muscular Dystrophy, Duchenne/therapy; Myostatin/genetics; Myostatin/metabolism; Signal Transduction

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Muscular Dystrophy, Duchenne / Activin Receptors, Type II / Myostatin / Molecular Targeted Therapy Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2012 Type: Article

Search on Google

XML

PubMed Links